PATIENT ENGAGEMENT OPEN FORUM - DAY 2 WORKSHOPS

It is now recognized that patient engagement is a major asset in clinical development, by making trials co-created with patients more acceptable, accessible and therefore more attractive to participate-in. This collaboration generates more consistent trials, improves trial recruitment rates, and speeds up the medicine development process which can lead to faster filings towards regulatory bodies and higher rates of approvals (a program co-created with patients has a 20% chance higher of obtaining Marketing Authorization[1]). Despite this recently measured success, R&D global activity is still facing major increases in difficulty and costs, and too few programs of research succeed in reaching the clinical development stage or go on to fail early on. These wasted resources result in a heavier burden on the entire healthcare system, with an increase in the price of the few drugs reaching the market, and extremely long waiting times for patients with urgent medical needs.

This combined with the already measurable and reported benefits of involving and co-creating with patients during clinical trials should inspire stakeholders to collaborate earlier in the medicines lifecycle. Research papers and guidance on this topic often refer to patient involvement 'across the medicines development continuum', however, in practice there are only a few examples of meaningful partnership working between patients and those delivering research throughout discovery and early clinical phases of development.

WORKSHOP 2 - HOW TO ENGAGE PATIENTS IN THE CLINICAL TRIAL PHASES

This workshop focuses on two specific activities in the clinical trial phases where patients can be involved in the process. By attending this workshop, you will be able to participate in the co-creation of how-to guides on the following topics:

1) how to best engage patients in the clinical trial protocol development, or
2) how to best engage patients in the selection, development and interpretation of clinical outcome assessment (COA) instruments.

In the first part of the workshop you will be introduced to the current structures and plans of these two how-to guides. You will then choose one group you are most interested to contribute in and will work together with the group to provide your input and suggestions to advance the content and next steps.

Your input and contribution will be used to help us take these how-to modules further. After this workshop, you can also choose to join in the review and validation rounds of the finalised how-to guides.

[1] The innovation imperative: the future of drug development, a study conducted by The Economist Intelligence Unit and commissioned by PAREXEL (https://druginnovation.eiu.com/)